Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

One of the more famous companies in this niche is CRISPR Therapeutics (NASDAQ: CRSP). Is this mid-cap company worth ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...

Bismuthene nanodiscs use mild heat to switch on gene editing that dismantles a tumor's heat defenses, creating a feedback loop that kills cancer cells more effectively.

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Study finds CRISPR restores the ability for cancer treatments to attack melanoma cancer cells with precision-guided gene edit that ignores healthy cells Wilmington, DE, OCTOBER 15, 2024 -- In a ...

Dr. Mark Pennesi looks on as staff at school's Casey Eye Institute perform the first-ever in vivo CRISPR gene edit procedure for the BRILLIANCE clinical trial in Portland. Kristyna Wentz-Graff/OHSU ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...